Trial reportBritish journal of haematology2021
Glucocorticoid use and risk of first and recurrent venous thromboembolism: self-controlled case-series and cohort study.
Trial report in British journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Cabozantinib and thromboembolism in patients with cancer: a systematic review, meta-analysis, and retrospective study.Blood advances · 2026Pooled it
- Thrombosis in Neuromuscular Medicine: Current Evidence, Unmet Needs, and Future Directions.Journal of clinical medicine · 2026Review
- Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France.Journal of neuromuscular diseases · 2026Article
- From Inflammation to Thrombosis: The Prothrombotic State and Cardiovascular Risk in Inflammatory Bowel Disease.Medicina (Kaunas, Lithuania) · 2026Review
- Venous thromboembolism in Cushing syndrome: current evidence and a practical thromboprophylaxis algorithm.Frontiers in endocrinology · 2026Review
- A Review of the Role of Neuroimaging in Neurotoxicity Monitoring in Children with Acute Lymphoblastic Leukemia.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan.Journal of cancer research and clinical oncology · 2025Article
- Predictive Factors for Pulmonary Embolism in Patients Undergoing Metabolic and Bariatric Surgery: Insights from the Latest MBSAQIP Data.Obesity surgery · 2025Article
- Thrombotic complications of glucocorticoids and anabolic steroids.Research and practice in thrombosis and haemostasis · 2025Review
- The burden of systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps.Allergy and asthma proceedings · 2025Review
- Venous thromboembolism in bullous pemphigoid: current evidence from an updated systematic review.Dermatology reports · 2025Article
- Normal Saline Push-Pause Advantage for Implanted Port Patency: A Comparative Study.Clinical journal of oncology nursing · 2025Article
- A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database.Scientific reports · 2025Article
- Article
- Before Coming to the Conclusion That Inclusion Body Myositis Is a Risk Factor for a Heart Attack, All Influencing Factors Must Be Taken Into Account.European journal of neurology · 2025Article
- Prevalence and incidence of comorbidities in patients with atopic dermatitis, psoriasis, alopecia areata, and vitiligo using a Japanese claims database.The Journal of dermatology · 2025Article
- A mendelian randomization study on the association between 731 types of immune cells and 91 types of blood cells with venous thromboembolism.Thrombosis journal · 2025Article
- [Limitations and challenges of glucocorticoids in the treatment of paroxysmal nocturnal hemoglobinuria].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Venous thromboembolism risk factors in pediatric patients with high-grade glioma: a multicenter retrospective study.Frontiers in pediatrics · 2025Article
- Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoid treatment increases venous thromboembolism (VTE) risk. Whether this is due to the medication or the underlying disease, or affects the risk of VTE recurrence, has been difficult to determine. The aim of our present study was to quantify the risk for first and recurrent VTE associated with oral glucocorticoids use, considering the underlying disease. A total of 2547 patients with VTE from the Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis (MEGA) study were linked to the Dutch Pharmaceutical Statistics register. The risk of first VTE during periods of exposure with oral glucocorticoids was estimated by the self-controlled case series method and that of recurrent VTE was examined in a cohort design. The incidence rate ratio (IRR) of first VTE in the period of glucocorticoid treatment was 3·51 [95% confidence interval (CI) 2·55-4·80]. This IRR was 2·53 (95% CI 1·10-5·72) in the week before treatment started, 5·28 (95% CI 2·89-9·53) in the first 7 days of treatment, remained elevated afterwards and decreased to 1·55 (95% CI 0·85-3·12) after 6 months, as compared to unexposed periods. The hazard ratio for recurrence was 2·72 (95% CI 1·64-4·78) in treatment periods as compared with no treatment. The increased risk of VTE associated with oral glucocorticoid treatment is due to a combined effect of the treatment and the underlying disease, remaining high during the first months of prescription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.